Non-invasive testing to profile tricuspid regurgitation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center observational program at Prince of Wales Hospital using non-invasive devices (ReDs Pro for lung fluid and transient elastography/FibroScan for liver stiffness) alongside standard cardiac imaging to phenotype tricuspid regurgitation. Eligible participants have at least moderate TR and are able to give consent, while patients with LVEF ≤40%, significant left-sided valvular disease, prior tricuspid interventions, or active liver disease are excluded. The approach aims to link extracardiac measures of congestion and liver stiffness with TR severity and heart-failure features, particularly HFpEF and atrial fibrillation. Findings will be descriptive and hypothesis-generating to help match patient features to emerging transcatheter tricuspid therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with \>=moderate TR
* able to consent for the study.

Exclusion Criteria:

1. LVEF \<=40%
2. Have significant left sided organic valvular heart disease (i.e. \>=moderate AS, \>=moderate MS, \>=moderate MR of organic or mixed aetiology), dysfunctional mitral valve replacement or aortic valve replacement
3. Prior tricuspid valve interventions (eg TriClip, tricuspid valve repair or replacement) (To allow accurate transient elastography)
4. Known hepatocellular carcinoma
5. Known portal vein thrombosis
6. Established liver cirrhosis with a known liver-related aetiology
7. Hepatitis C infection and not on treatment
8. Uncontrolled hepatitis (e.g. hepatitis B infection, autoimmune hepatitis)
9. Fatty liver with evidence of non-alcoholic fatty liver disease or cirrhosis (to allow accurate non-invasive lung fluid assessment)
10. recent rib fracture (\<3 months) with or without flail chest
11. BMI \<20 or \>36
12. Height \<155cm or \>195cm
13. Patients with right lung tumor
14. Patients with right sided pacemaker
15. Patients with known underlying exudative right pleural effusion

Where it's running

• Prince of Wales Hospital
  Hong Kong, Shatin, Hong Kong Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 3D Echocardiography to See How CIEDs May Worsen Tricuspid Regurgitation

  This study tests whether different CIEDs (leadless pacemakers, LBBaP, and conventional pacemakers) differ in causing worsening tricuspid regurgitation, using 3D heart imaging.

  Recruiting Samsung Medical Center · Seoul, Seoul · NCT07793916

• Compare leadless and left bundle branch pacemakers for heart and valve function

  This study tests whether leadless pacemakers or left bundle branch area pacing better preserve heart and tricuspid valve function in adults needing a pacemaker.

  Recruiting Guy's and St Thomas' NHS Foundation Trust · London · NCT07534917

• TriClip for treating tricuspid regurgitation in Japan

  This study will see if the TriClip device is safe and helps people in Japan with symptomatic severe tricuspid regurgitation when used in routine clinical care.

  Recruiting Abbott Medical Devices · Suita, Osaka · NCT07509658

• Impact of transcatheter tricuspid valve repair on kidneys, strength, and activity in older adults

  This study will try catheter-based tricuspid valve repair (TEER) in older adults with severe symptomatic tricuspid regurgitation to see if kidney function, fluid overload, and physical activity improve.

  Recruiting Robert Bosch Medical Center · Stuttgart · NCT07464106

• TARGET 2.0: Cardiovalve TR replacement for tricuspid regurgitation

  This study will test a percutaneously delivered Cardiovalve tricuspid replacement via the femoral vein in adults with symptomatic severe secondary tricuspid regurgitation who are high risk for open-heart surgery.

  Recruiting Cardiovalve Ltd. · Bonn · NCT07334691

• Pivot Extend device to treat severe tricuspid regurgitation

  This trial will try the Pivot Extend device in adults with severe, symptomatic tricuspid regurgitation to see if it safely reduces valve leakage and improves symptoms.

  Recruiting Tau-MEDICAL Co., Ltd. · Macquarie Park, New South Wales · NCT07172477

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.